BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• BioNTech closed 2025 with strong momentum through consistent execution in R&D, partnerships, acquisitions, and strong financial position while advancing next wave of innovations including combination studies

  80% confidence

• BioNTech expects moderate decline in Comirnaty revenues in 2026 compared to 2025, reflecting current COVID-19 vaccine market dynamics influenced by changing vaccination recommendations especially in the United States and transition from multi-year contracts to private markets

  80% confidence

• BioNTech has positioned itself as a biopharmaceutical company with multiple programs in late-stage clinical development

  80% confidence

• BioNTech currently expects no revenues from oncology product sales in 2026

  80% confidence

• 2026 is a year when scientific progress becomes tangible results for BioNTech, with milestones including late-stage data releases, early clinical trial results for combination therapies, and launch of additional Phase 3 trials

  80% confidence

• BioNTech expects collaboration revenues from Bristol Myers Squibb partnership in 2026 to be essentially at 2025 levels

  80% confidence

• Positive clinical trial results could pave the way for multiple short- and medium-term product launches, bringing BioNTech closer to helping patients with various cancer types

  80% confidence

• BioNTech expects at least 17 late-stage clinical data readouts through 2030 and beyond, including from registration-enabling studies, to inform decisions on multiple potential product launches and establish BioNTech as a multi-product oncology company by 2030

  80% confidence

• BioNTech plans to start six additional Phase 3 clinical trials in 2026, bringing total expected Phase 3 trials to 15 by year-end

  80% confidence

Data points we hold from this source

Citado en estos reportajes de Via News

• China's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, Regeneron →